About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: REGN
- CUSIP: 75886F10
- Previous Close: $371.61
- 50 Day Moving Average: $363.10
- 200 Day Moving Average: $385.02
- 52-Week Range: $325.35 - $452.96
- Trailing P/E Ratio: 48.27
- Foreward P/E Ratio: 23.67
- P/E Growth: 1.53
- Market Cap: $39.19B
- Outstanding Shares: 105,461,000
- Beta: 1.44
- Net Margins: 18.10%
- Return on Equity: 22.51%
- Return on Assets: 14.58%
Companies Related to Regeneron Pharmaceuticals:
- Debt-to-Equity Ratio: 0.08%
- Current Ratio: 2.56%
- Quick Ratio: 2.24%
What is Regeneron Pharmaceuticals' stock symbol?
Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2017?
24 brokers have issued 1 year price targets for Regeneron Pharmaceuticals' stock. Their forecasts range from $345.00 to $598.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $449.52 in the next year.
When will Regeneron Pharmaceuticals announce their earnings?
Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
What are analysts saying about Regeneron Pharmaceuticals stock?
Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
According to Zacks Investment Research, "Regeneron’s fourth-quarter results were disappointing with the company missing on both earnings and revenues estimates. Moreover, the guidance for Eylea was also weak. Regeneron suffered a major blow when the U.S District Court in Delaware granted Amgen request for a permanent injunction prohibiting the sale of PCSK9 inhibitor, Praluent. However, on Feb 8, the United States Court of Appeals for the Federal Circuit stayed the injunction appeal. Hence, Regeneron and Sanofi will continue marketing, selling, and manufacturing Praluent in the U.S. during the appeal process. Although sales of Praluent have failed to impress due to the present payer utilization management restrictions in the U.S. and limited market access in Europe, the drug is still expected to have blockbuster potential. Investors should focus on late stage pipeline catalysts - dupilumab and sarilumab. Shares of the company have also underperformed the industry." (2/15/2017)
Cowen and Company analysts commented, "This morning REGN reported Q4 earnings." (2/9/2017)
Chardan Capital analysts commented, "We believe the news is an important long-term negative, as REGN (Sell, PT$325) is increasingly exposed to what we expect could be a 2017+ theme in wet AMD of treatment burden reduction." (9/30/2016)
Who owns Regeneron Pharmaceuticals stock?
Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (7.46%), State Street Corp (3.09%), Sands Capital Management LLC (2.19%), Artisan Partners Limited Partnership (1.80%), Loomis Sayles & Co. L P (1.63%) and Polen Capital Management LLC (1.28%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Marc Tessier-Lavigne, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Peter Powchik, Plew Daniel P Van, Robert Alexander Ingram, Robert J Terifay and Sanofi.
Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?
Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Sands Capital Management LLC, Guggenheim Capital LLC, Pinnacle Associates Ltd., Ithaka Group LLC, Teachers Retirement System of The State of Kentucky, Baillie Gifford & Co. and GSA Capital Partners LLP. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein and Plew Daniel P Van.
Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?
Regeneron Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Polen Capital Management LLC, Renaissance Technologies LLC, Federated Investors Inc. PA, Russell Investments Group Ltd., Franklin Resources Inc., DSM Capital Partners LLC and Southpoint Capital Advisors LP.
How do I buy Regeneron Pharmaceuticals stock?
Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Regeneron Pharmaceuticals stock cost?
One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $371.61.